Home/Pipeline/Narcolepsy Study

Narcolepsy Study

Narcolepsy

Phase 4Completed/HighlightedN/A

Key Facts

Indication

Narcolepsy

Phase

Phase 4

Status

Completed/Highlighted

Company

Science 37

About Science 37

Science 37's mission is to make clinical research accessible to anyone, anywhere, anytime by pioneering a decentralized clinical trial (DCT) model. Its key achievement is establishing a unique, FDA-inspected Direct-to-Patient Site, which has successfully supported over 185 trials and consistently ranks as a top-enrolling site. The company's strategy leverages its proprietary technology platform and a nationwide network of research-grade nurses to orchestrate hybrid and fully decentralized trials, offering sponsors a proven path to faster, more diverse patient recruitment and retention.

View full company profile

Therapeutic Areas

Cardiovascular CNS Dermatology Endocrinology Gastroenterology Hematology Immunology Infectious Disease Men’s Health Musculoskeletal Oncology Ophthalmology Respiratory Urology Women’s Health Pediatrics

Other Narcolepsy Drugs

Drug	Company	Phase	Status
Pitolisant Tablets	Lupin	Approved (Tentative)	Tentative FDA Approval
Pitolisant (Wakix®/Ozawade®)	Bioprojet SCR	Approved	Active
Sodium Oxybate (one-nightly)	D&A Pharma	Development	Active